Ras is the name given to a family of related proteins which is ubiquitously expressed in all cell lineages and organs.All members of the Ras protein family are involved in signal transmission within cells and are members of the small GTPase protein class. Ras is the representative member of the Ras superfamily, a group of proteins that all share a common 3D structure and control a variety of cell behaviors. Incoming signals that activate Ras then activate other proteins, which in turn activate genes necessary for cell growth, differentiation, and survival. Ras proteins that are permanently activated can therefore be produced as a result of ras gene mutations.Even in the absence of incoming signals, this may result in unintended and excessive signaling within the cell. Overactive Ras signaling can ultimately result in cancer because these signals cause cell growth and division. The most prevalent oncogenes in human cancer are the 3 Ras genes (HRAS, KRAS, and NRAS), and Ras inhibitors are being researched as a potential treatment for cancer and other conditions characterized by Ras overexpression.
Structure | Cat No. | Product Name | CAS No. | Product Description |
---|---|---|---|---|
V87119 | (+)-Oxanthromicin | 1616622-08-2 | (+)-Oxanthromicin (Compound 1) can mislocalize oncogenic mutant K-Ras from the plasma membrane in intact Madin-Darby canine kidney (MDCK) cells, thereby exerting antitumor activity. | |
V89591 | (RS)-G12Di-1 | (RS)-G12Di-1 is a selective covalent inhibitor of K-Ras-G12D. | ||
V51415 | (S)-JDQ-443 ((S)-NVP-JDQ443) | 2653994-10-4 | (S)-JDQ-443 is an isomer of JDQ-443 . | |
V51476 | CFL-137 | 708-06-5 | CFL-137 is a selective KRasG12C inhibitor. | |
V51475 | CFL-120 | 18711-15-4 | CFL-120 is a selective KRasG12C inhibitor. | |
V87108 | 8-CPT-2'-O-Me-cAMP | 510774-50-2 | 8-CPT-2'-O-Me-cAMP is a Rap1 activator. | |
V87118 | 8-pHPT-2'-O-Me-cAMP | 612513-15-2 | 8-pHPT-2'-O-Me-cAMP is a cAMP analog and an Epac agonist. | |
V86758 | ADT-007 | 1945941-09-2 | ADT-007 is a potent, orally active pan-RAS inhibitor with strong anticancer effects. | |
V93209 | AM-001 | 340817-81-4 | AM-001 is a noncompetitive Epac1 inhibitor that blocks the activation of Rap1, a downstream effector of Epac1, in cultured cells. | |
V87112 | Anticancer agent 207 | Anticancer agent 207 (compound 10b) is a potent anticancer agent. | ||
V11400 | Antineoplaston A 10 | 91531-30-5 | Antineoplaston A10 exists naturally in the human body and is an inhibitor (blocker/antagonist) of Ras. | |
V51547 | Antitumor compound 5a | 2907704-65-6 | Antitumor compound 5a, has an IC50 value of 2.62 µM, meaning that it inhibits MCF-7 breast cancer cells. | |
V83594 | ARN22089 | 2248691-29-2 | ||
V93277 | ARN25062 | 3036492-85-7 | ARN25062 (compound 27) is a CDC42/RHOJ inhibitor with antitumor activity. | |
V51473 | ARS-1323-alkyne | 2436544-27-1 | ARS-1323-alkyne, a switch-II pocket (S-IIP) inhibitor, a conformationally specific chemical reporter of the KRASG12C nucleotide state in living cells, is a switch-II pocket (S-IIP) inhibitor. | |
V51452 | ARS-2102 | 2098509-21-6 | ARS-2102 is a potent covalent KRAS G12C inhibitor for cancer research. | |
V51458 | ASP-2453 | 2241719-73-1 | ASP2453 is a novel and covalent inhibitor of KRAS G12C. | |
V83369 | ASP6918 | |||
V77220 | AZD4747 | 2489226-14-2 | AZD4747 is a selective, BBB (blood-brain barrier) permeable/penetrable inhibitor of the mutant GTPase KRASG12C. | |
V86759 | BBO-8520 | 2893809-51-1 | BBO-8520 is a direct small molecule covalent inhibitor targeting KRASG12C, with high oral availability, and has both KRASG12C (OFF) inhibitor properties and the effect of blocking KRAS G12C (ON) signaling. |